Patient Education on Oral Anticoagulation
Abstract
:1. Introduction
2. Anticoagulation Management Services
3. Patient Counseling
4. Anticoagulation Information
- The drug’s brand and generic name and, when needed, its therapeutic class
- The drug’s purpose and how it pertains to thrombus formation
- The drug’s anticipated onset and what to do if the expected result does not occur
- The drug’s route, dosage form, dose, frequency, and duration of treatment
- Directions for preparing and using the drug (such as low-molecular weight heparin)
- Missed-dose management
- Precautions to be aware of when using the drug and the potential measures to decrease bleeding risk and trauma
- Common side effects that may occur (including signs and symptoms of bleeding) and steps to follow if they occur, actions to prevent or reduce their occurrence, and what to do if they occur, including when to notify a healthcare professional
- Strategies for self-monitoring and the importance of regular monitoring to reduce bleeding and thrombosis
- Potential drug–drug (including OTC), drug–food, and drug–disease interactions or contraindications
- Need to inform provider if you are pregnant or plan to become pregnant
- Need to inform provider before a procedure or hospitalization
- Need to notify all health care providers of use
- Need to wear medical identification
- Importance of not stopping without consulting health care provider
- Need to consult health care provider before starting any new drug
- Inform provider of all medication changes, including over-the-counter and herbals
- Importance of taking exactly as prescribed and use of an adherence aid if needed
- Prescription refills authorized and the process for obtaining refills
- Proper drug storage and disposal
- Other helpful information unique to the specific patient or therapy
5. Specific Drug Considerations
6. Conclusions
- Regular INR tests are needed to ensure warfarin is working properly
- The goal INR range is often between 2 and 3; risk for clotting is greater when INRs are less than 2, risk for bleeding is higher when INRs are greater than 3; doses of warfarin are modified based on INR test results
- Each strength of warfarin has a unique color; with each refill make sure the tablets are the same color
- Foods with a lot of vitamin K like kale, collard greens, and spinach may interfere with warfarin; you do not need to avoid foods with vitamin K, but need to try to maintain consistent dietary habits on a weekly basis
- Alcohol increases the risk for bleeding and interferes with warfarin therapy; no more than 1–2 drinks per day, and avoid binge drinking
Conflicts of Interest
References
- How-to Guide: Prevent Harm from High-Alert Medications; Institute for Healthcare Improvement: Cambridge, MA, USA, 2012; Available online: http://www.ismp.org/Tools/highalertmedications.pdf (accessed on 29 March 2018).
- Piazza, G.; Nguyen, T.N.; Cios, D.; Labreche, M.; Hohlfelder, B.; Fanikos, J.; Fiumara, K.; Goldhaber, S.Z. Anticoagulation-associated adverse drug events. Am. J. Med. 2011, 124, 1136–1142. [Google Scholar] [CrossRef] [PubMed]
- The Joint Commission. National Patient Safety Goals 2018. Available online: https://www.jointcommission.org/assets/1/6/NPSG_Chapter_HAP_Jan2018.pdf (accessed on 19 April 2018).
- Garcia, D.A.; Witt, D.M.; Hylek, E.; Wittkowsky, A.K.; Nutescu, E.A.; Jacobson, A.; Moll, S.; Merli, G.J.; Crowther, M.; Earl, L.; et al. Delivery of optimized anticoagulant therapy: Consensus statement from the Anticoagulation Forum. Ann. Pharmacother. 2008, 42, 979–988. [Google Scholar] [CrossRef] [PubMed]
- Saokaew, S.; Permsuwan, U.; Chaiyakunapruk, N.; Nathisuwan, S.; Sukonthasarn, A. Effectiveness of pharmacist-participated warfarin therapy management: A systematic review and metaanalysis. J. Thromb. Haemost. 2010, 8, 2418–2427. [Google Scholar] [CrossRef] [PubMed]
- Bishop, M.A.; Streiff, M.B.; Ensor, C.R.; Tedford, R.J.; Russell, S.D.; Ross, P.A. Pharmacist-managed international normalized ratio patient self-testing is associated with increased time in therapeutic range in patients with left ventricular assist devices at an academic medical center. ASAIO J. 2014, 60, 193–198. [Google Scholar] [CrossRef] [PubMed]
- Bungard, T.J.; Gardner, L.; Archer, S.L.; Hamilton, P.; Ritchie, B.; Tymchak, W.; Tsuyuki, R.T. Evaluation of a pharmacist-managed anticoagulation clinic: Improving patient care. Open Med. 2009, 3, e16–e21. [Google Scholar] [PubMed]
- Challen, L.; Agbahiwe, S.; Cantieri, T.; Olivetti, J.G.; Mbah, T.; Mendoza-Becerra, Y.; Munoz, C.; Nguyen, M.; Partee, K.; Lal, L.; et al. Impact of Point-of-Care Implementation in Pharmacist-Run Anticoagulation Clinics within a Community-Owned Health System: A Two-Year Retrospective Analysis. Hosp. Pharm. 2015, 50, 783–788. [Google Scholar] [CrossRef] [PubMed]
- Chilipko, A.A.; Norwood, D.K. Evaluating warfarin management by pharmacists in a community teaching hospital. Consult. Pharm. 2014, 29, 95–103. [Google Scholar] [CrossRef] [PubMed]
- Garton, L.; Crosby, J.F. A retrospective assessment comparing pharmacist-managed anticoagulation clinic with physician management using international normalized ratio stability. J. Thromb. Thrombolysis 2011, 32, 426–430. [Google Scholar] [CrossRef] [PubMed]
- Holden, J.; Holden, K. Comparative effectiveness of general practitioner versus pharmacist dosing of patients requiring anticoagulation in the community. J. Clin. Pharm. Ther. 2000, 25, 49–54. [Google Scholar] [CrossRef] [PubMed]
- Young, S.; Bishop, L.; Twells, L.; Dillon, C.; Hawboldt, J.; O’Shea, P. Comparison of pharmacist managed anticoagulation with usual medical care in a family medicine clinic. BMC Fam. Pract. 2011, 12, 88. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ingram, S.J.; Kirkdale, C.L.; Williams, S.; Hartley, E.; Wintle, S.; Sefton, V.; Thornley, T. Moving anticoagulation initiation and monitoring services into the community: Evaluation of the Brighton and hove community pharmacy service. BMC Health Serv. Res. 2018, 18, 91. [Google Scholar] [CrossRef] [PubMed]
- Harrison, J.; Shaw, J.P.; Harrison, J.E. Anticoagulation management by community pharmacists in New Zealand: An evaluation of a collaborative model in primary care. Int. J. Pharm. Pract. 2015, 23, 173–181. [Google Scholar] [CrossRef] [PubMed]
- Locke, C.; Ravnan, S.L.; Patel, R.; Uchizono, J.A. Reduction in warfarin adverse events requiring patient hospitalization after implementation of a pharmacist-managed anticoagulation service. Pharmacotherapy 2005, 25, 685–689. [Google Scholar] [CrossRef] [PubMed]
- Rudd, K.M.; Dier, J.G. Comparison of two different models of anticoagulation management services with usual medical care. Pharmacotherapy 2010, 30, 330–338. [Google Scholar] [CrossRef] [PubMed]
- Holbrook, A.; Schulman, S.; Witt, D.M.; Vandvik, P.O.; Fish, J.; Kovacs, M.J.; Svensson, P.J.; Veenstra, D.L.; Crowther, M.; Guyatt, G.H. Evidence-based management of anticoagulant therapy: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012, 141 (Suppl. 2), e152S–e184S. [Google Scholar] [CrossRef] [PubMed]
- Wittkowsky, A.K. Impact of target-specific oral anticoagulants on transitions of care and outpatient care models. J. Thromb. Thrombolysis 2013, 35, 304–311. [Google Scholar] [CrossRef] [PubMed]
- Zdyb, E.G.; Courtney, D.M.; Malik, S.; Schmidt, M.J.; Lyden, A.E. Impact of Discharge Anticoagulation Education by Emergency Department Pharmacists at a Tertiary Academic Medical Center. J. Emerg. Med. 2017, 53, 896–903. [Google Scholar] [CrossRef] [PubMed]
- Dharmarajan, T.S.; Gupta, A.; Baig, M.A.; Norkus, E.P. Warfarin: Implementing its safe use in hospitalized patients from nursing homes and community through a performance improvement initiative. J. Am. Med. Dir. Assoc. 2011, 12, 518–523. [Google Scholar] [CrossRef] [PubMed]
- Wang, Y.; Kong, M.C.; Lee, L.H.; Ng, H.J.; Ko, Y. Knowledge, satisfaction, and concerns regarding warfarin therapy and their association with warfarin adherence and anticoagulation control. Thromb. Res. 2014, 133, 550–554. [Google Scholar] [CrossRef] [PubMed]
- Manzoor, B.S.; Lee, T.A.; Sharp, L.K.; Walton, S.M.; Galanter, W.L.; Nutescu, E.A. Real-World Adherence and Persistence with Direct Oral Anticoagulants in Adults with Atrial Fibrillation. Pharmacotherapy 2017, 37, 1221–1230. [Google Scholar] [CrossRef] [PubMed]
- Heidbuchel, H.; Verhamme, P.; Alings, M.; Antz, M.; Hacke, W.; Oldgren, J.; Sinnaeve, P.; Camm, A.J.; Kirchhof, P. European Heart Rhythm Association. European Heart Rhythm Association practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013, 15, 625–651. [Google Scholar] [CrossRef] [PubMed]
- Burnett, A.E.; Mahan, C.E.; Vazquez, S.R.; Oertel, L.B.; Garcia, D.A.; Ansell, J. Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTEtreatment. J. Thromb. Thrombolysis 2016, 41, 206–232. [Google Scholar] [CrossRef] [PubMed]
- Simon, J.; Hawes, E.; Deyo, Z.; Bryant Shilliday, B. Evaluation of prescribing and patient use of target-specific oral anticoagulants in the outpatient setting. J. Clin. Pharm. Ther. 2015. [Google Scholar] [CrossRef] [PubMed]
- Howard, M.; Lipshutz, A.; Roess, B.; Hawes, E.; Deyo, Z.; Burkhart, J.; Moll, S.; Shilliday, B. Identification of Risk Factors for Inappropriate and Suboptimal Initiation of Direct Oral Anticoagulants. J. Thromb. Thrombolysis 2017, 43, 149–156. [Google Scholar] [CrossRef] [PubMed]
- Eliquis [package insert]; Bristol-Myers Squibb Company: Princeton, NJ, USA, 2012.
- Pradaxa [package insert]; Boehringer Ingelheim Pharmaceuticals Inc.: Ridgefield, CT, USA, 2010.
- Xarelto [package insert]; Janssen Pharmaceuticals, Inc.: Titusville, NJ, USA, 2011.
- Savaysa [package insert]; Daiichi Sankyo, Inc.: Basking Ridge, NJ, USA, 2017.
- Chan, L.L.; Crumpler, W.L.; Jacobson, A.K. Implementation of pharmacist-managed anticoagulation in patients receiving newer anticoagulants. Am. J. Health Syst. Pharm. 2013, 70, 1285–1286, 1288. [Google Scholar] [CrossRef] [PubMed]
- Lane, D.A.; Aguinaga, L.; Blomström-Lundqvist, C.; Boriani, G.; Dan, G.A.; Hills, M.T.; Hylek, E.M.; LaHaye, S.A.; Lip, G.Y.; Lobban, T.; et al. Cardiac tachyarrhythmias and patient values and preferences for their management: The European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE). Europace 2015, 17, 1747–1769. [Google Scholar] [CrossRef] [PubMed]
- James, J. Patient engagement. Health Affairs 2013. Available online: http://www.healthaffairs.org/healthpolicybriefs/brief.php?brief_id=86 (accessed on 28 January 2018).
- Hibbard, J.H.; Greene, J.; Overton, V. Patients with lower activation associated with higher costs; delivery systems should know their patients’ ‘‘Scores’’. Health Aff. 2013, 32, 216–222. [Google Scholar] [CrossRef] [PubMed]
- Institute of Medicine. Committee on Identifying and Preventing Medication Errors. Preventing Medication Errors; The National Academies Press: Washington, DC, USA, 2006. [Google Scholar]
- American Society of Health-System Pharmacy. ASHP Guidelines on Pharmacist-Conducted Patient Education and Counseling. Available online: https://www.ashp.org/DocLibrary/BestPractices/OrgGdlPtEduc.aspx (accessed on 29 March 2018).
- American Society of Hospital Pharmacists. ASHP statement on pharmaceutical care. Am. J. Hosp. Pharm. 1993, 50, 1720–1723. Available online: http://www.ashp.org/doclibrary/bestpractices/orgstpharmcare.aspx (accessed on 29 March 2018).
- Johnson, A.; Sandford, J.; Tyndall, J. Written and verbal information versus verbal information only for patients being discharged from acute hospital settings to home. Cochrane Database Syst. Rev. 2003. [Google Scholar] [CrossRef] [PubMed]
- Institute for Safe Medication Practices (ISMP). 2003. Available online: https://www.ismp.org/Survey/surveyresults/NursingSurvey.asp (accessed on 28 January 2018).
- Health Literacy in Pharmacy; Agency for Healthcare Research and Quality: Rockville, MD, USA. Available online: http://www.ahrq.gov/professionals/education/curriculum-tools/pharmlitqi/ppt-slides.html (accessed on 29 March 2018).
- Davis, T.C.; Wolf, M.S.; Bass, P.F., III; Thompson, J.A.; Tilson, H.H.; Neuberger, M.; Parker, R.M. Literacy and misunderstanding prescription drug labels. Ann. Intern. Med. 2006, 145, 887–894. [Google Scholar] [CrossRef] [PubMed]
- Hernández Madrid, A.; Potpara, T.S.; Dagres, N.; Chen, J.; Larsen, T.B.; Estner, H.; Todd, D.; Bongiorni, M.G.; Sciaraffiam, E.; Proclemerm, A.; et al. Differences in attitude, education, and knowledge about oral anticoagulation therapy among patients with atrial fibrillation in Europe: Result of a self-assessment patient survey conducted by the European Heart Rhythm Association. Europace 2016, 18, 463–467. [Google Scholar] [CrossRef] [PubMed]
- Anticoagulation Toolkit: Reducing Adverse Drug Events & Potential Adverse Drug Events with Unfractionated Heparin, Low Molecular Weight Heparins and Warfarin. Available online: http://excellence.acforum.org/sites/default/files/Purdue%20Univ%20Anticoag%20Toolkit.pdf (accessed on 17 January 2018).
- Moreland, C.J.; Kravitz, R.L.; Paterniti, D.A.; Li, C.S.; Lin, T.C.; White, R.H. Anticoagulation education: Do patients understand potential medication-related emergencies? Jt. Comm. J. Qual. Patient Saf. 2013, 39, 22–31. [Google Scholar] [CrossRef]
- Witt, D.M.; Clark, N.P.; Kaatz, S.; Schnurr, T.; Ansell, J.E. Guidance for the practical management of warfarin therapy in the treatment of venous thromboembolism. J. Thromb. Thrombolysis 2016, 41, 187–205. [Google Scholar] [CrossRef] [PubMed]
Drug | Warfarin | Dabigatran | Rivaroxaban | Apixaban | Edoxaban |
---|---|---|---|---|---|
Dosing Frequency (For venousthromboembolism treatment or atrial fibrillation thromboprophylaxis) | Daily, adjusted based on INR | Twice daily | Daily or twice daily depending on indication | Twice daily | Daily |
Missed Dose | Take if before midnight on the same day | Take as soon as possible (asap) on same day but at least 6 h before next scheduled dose | If missed a 15 mg tablet, take asap but can take two 15 mg tablets together. Patients on once daily regimen should take asap on same day. | Take asap on same day | Take asap on same day |
Administration | With or without food | With a full glass of water; with or without food | With food | With or without food | With or without food |
Weekly pill box | Can aid adherence | MUST store in original container and keep sealed. | Can aid adherence | Can aid adherence | Can aid adherence |
Drug-Drug Interactions | Numerous; primarily via CYP2C9; minor pathways include CYP2C8, 2C18, 2C19, 1A2, and 3A4 | Important drug:drug interactions: P-gp inducers and inhibitors (especially if renal function compromised) | Avoid dual P-gp and strong CYP 3A4 inducers or inhibitors | Avoid dual P-gp and strong CYP 3A4 inducers or inhibitors | Important drug:drug interactions: P-gp inducers and inhibitors |
Can you crush? | Yes | No; Swallow whole; do not cut, open, or crush | Yes | Yes | Yes |
© 2018 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Hawes, E.M. Patient Education on Oral Anticoagulation. Pharmacy 2018, 6, 34. https://doi.org/10.3390/pharmacy6020034
Hawes EM. Patient Education on Oral Anticoagulation. Pharmacy. 2018; 6(2):34. https://doi.org/10.3390/pharmacy6020034
Chicago/Turabian StyleHawes, Emily M. 2018. "Patient Education on Oral Anticoagulation" Pharmacy 6, no. 2: 34. https://doi.org/10.3390/pharmacy6020034
APA StyleHawes, E. M. (2018). Patient Education on Oral Anticoagulation. Pharmacy, 6(2), 34. https://doi.org/10.3390/pharmacy6020034